Genmab — Juni 2016
-
Danske Bank hæver målpris på Genmab fra 1300 til 1450.
-
Fra Jefferies: "CASTOR Data Impress at ASCO Underscoring
Darzalex as a Standard of Care". Og så beholder de køb og målpris 1150???? -
Har hun ikke fået en forkert graf på ?? Den viser da ikke ath
http://play.borsen.dk/social/57541d69725ed7540a0d6832 -
-
Fra Danske: "We believe the detailed data exceeded our high
expectations and even improved the outlook in frontline MM from subgroup
observations. We keep our Buy and lift our 12M TP to DKK1,450 (DKK1,300)." -
Fra Danske: "Celgene validates daratumumab. Celgene will commence combination trials with
its durvalumab and daratumumab in RRMM (MM 003 trial) – a clear validation from
a key competitor – and it is our impression after talking with Celgene’s scientific
staff at ASCO that it is likely to commence additional clinical trials to combine
durvalumab with daratumumab." -
Desuden giver både dette og ligeledes det PR kort viste en præklinisk slide på - altså kombination af DVD+R må give fantastiske resultater. Vi har ikke helt denne kombi i klinikken endnu, men næste i form af Cassiopeia (VTD+Dara). Nok ikke den mest effektfulde kombi af fire, men helt sikkert den billigste
-
pt 1251
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind